Follow-up and end points in the Euro-Lupus Nephritis Trial cohort at 10 years*
| All | IVCY | ||
| High dose | Low dose | ||
| Randomised | 90 | 46 | 44 |
| Lost to follow-up | 6 | 3 | 3 |
| Follow-up (months), mean (SD) | 115 (30) | 119 (27) | 111 (33) |
| Age (years), mean (SD) | 41 (11) | 40 (11) | 42 (10) |
| Deaths | 7 | 2 | 5 |
| SDSC | 11 | 5 | 6 |
| ESRD | 6 | 4 | 2 |
Mean follow-up time was calculated for the 90 patients at their last follow-up date. Mean age at follow-up was calculated for the 77 non-lost, living patients. By definition, the six patients with ESRD were included in the group of 11 patients with SDSC.
*Figures are numbers of patients except where stated otherwise.
ESRD, end-stage renal disease; IVCY, intravenous cyclophosphamide; SDSC, sustained doubling of serum creatinine.